Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-506 DDI Study with Midazolam in Healthy Males
NCT05238948Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Feb 2022
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CKD-506 in rheumatoid arthritis (RA), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration of Midazolam at 24 hours and Area Under Curve of Midazolam at 24 hours. Started Feb 2022; status: completed.
02
Drugs
CKD-506
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05238948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238948.